Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 3
1987 1
1988 1
1989 3
1990 2
1991 1
1993 3
1994 6
1995 4
1996 11
1997 4
1998 8
1999 8
2000 13
2001 3
2002 14
2003 23
2004 24
2005 26
2006 30
2007 34
2008 40
2009 53
2010 47
2011 64
2012 68
2013 97
2014 112
2015 136
2016 147
2017 154
2018 152
2019 198
2020 264
2021 294
2022 329
2023 81
Text availability
Article attribute
Article type
Publication date

Search Results

2,171 results
Results by year
Filters applied: . Clear all
Page 1
Immunotherapies for hepatocellular carcinoma.
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Llovet JM, et al. Among authors: zhu ax. Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11. Nat Rev Clin Oncol. 2022. PMID: 34764464 Review.
Biliary tract cancer.
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Valle JW, et al. Among authors: zhu ax. Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7. Lancet. 2021. PMID: 33516341 Review.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Cheng AL, et al. Among authors: zhu ax. J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11. J Hepatol. 2022. PMID: 34902530 Free article. Clinical Trial.
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Yang C, et al. Among authors: zhu ax. Nat Rev Gastroenterol Hepatol. 2022 Nov 11. doi: 10.1038/s41575-022-00704-9. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2022. PMID: 36369487 Review.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Cryo-EM structure of human glucose transporter GLUT4.
Yuan Y, Kong F, Xu H, Zhu A, Yan N, Yan C. Yuan Y, et al. Among authors: zhu a. Nat Commun. 2022 May 13;13(1):2671. doi: 10.1038/s41467-022-30235-5. Nat Commun. 2022. PMID: 35562357 Free PMC article.
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, Sikder D, Senechal B, Wang X, Travis WD, Gönen M, Rudin CM, Brentjens RJ, Jones DR, Sadelain M. Adusumilli PS, et al. Among authors: zhu a. Cancer Discov. 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407. Epub 2021 Jul 15. Cancer Discov. 2021. PMID: 34266984 Free PMC article. Clinical Trial.
2,171 results